Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is on the market as monotherapy in both subcutaneous along with oral dosage kind (first accepted oral GLP-1 receptor agonist). It's been approved to be a 2nd line remedy option for better glycaemic Command in variety 2 diabetic issues and at present https://bonos998eqb1.ageeksblog.com/profile